A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Plain-language summary

This is a follow-up study that monitors the long-term safety of a gene therapy called RetinoStat in people with age-related macular degeneration who previously received it. It enrolled patients who had a subretinal injection of RetinoStat as part of the earlier RS1/001/10 protocol. The study is being carried out in Phase 1; it is not currently recruiting but is still ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Active, not recruiting

Sponsor

Oxford BioMedica

Intervention

RetinoStat

Start date

8/1/2012

Estimated completion

3/1/2029

Countries

United States

Related genes

Locations

• Iowa City, United States
• Baltimore, United States
• Portland, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Must have received a subretinal injection of RetinoStat
* Must have been enrolled in Protocol RS1/001/10

Exclusion Criteria:

* Did not receive RetinoStat® as part of the RS1/001/10 protocol